Pharmacologic agents for smoking cessation: A clinical review

Dilip R Patel1
Cynthia Feucht2
Lesley Reid1
Neil D Patel1

1Michigan State University, Kalamazoo Center for Medical Studies, Kalamazoo, MI, USA; 2Ferris State University College of Pharmacy, Kalamazoo, MI, USA

Abstract: Tobacco use has been clearly demonstrated to have negative health consequences. Smoking cigarettes is the predominant method of tobacco use. The tar contained within cigarettes and other similar products is also harmful. Other tarless tobacco containing products do exist but carry no significantly decreased risk. While nicotine is considered to be principally responsible for tobacco addiction, other chemicals in the cigarette smoke including acetaldehyde may contribute to the addictive properties of tobacco products. The adverse health consequences of tobacco use have been well documented. Studies have shown that a combined behavioral and pharmacological approach is more effective in smoking cessation than either approach alone. Pharmacotherapy can achieve 50% reduction in smoking. With pharmacotherapy the estimated 6-month abstinence rate is about 20%, whereas it is about 10% without pharmacotherapy. The first-line of drugs for smoking cessation are varenicline, bupropion sustained release, and nicotine replacement drugs, which are approved for use in adults. Data are insufficient to recommend their use in adolescents. This article reviews the use of pharmacological agents used for smoking cessation. A brief overview of epidemiology, chemistry, and adverse health effects of smoking is provided.

Keywords: smoking, tobacco, nicotine, nicotine addiction, varenicline, bupropion sustained release, nicotine replacement therapy, electronic cigarettes

Introduction

The tobacco plant is native to South America, Mexico, and the West Indies.1 The American Indians used various forms of tobacco for its medicinal properties for hundreds of years before the discovery of the New World by Christopher Columbus.1 The common tobacco, Nicotiana tabacum, is named after Jean Nicot, the French ambassador to Lisbon, who is believed to have sent its seeds to Catherine de Medicis, the queen consort and regent of France in 1566.1 Nicotine was first extracted in its crude form in 1571, purified form in 1928, and synthesized in a laboratory in 1904.1 Over the decades, the causative role of smoking, and other forms of tobacco use, in cancer has been well-established. This article reviews the pharmacological agents currently used for smoking cessation. These include the various forms of nicotine replacement products, varenicline, bupropion sustained release, nortriptyline, and clonidine. A brief overview of the epidemiology of smoking, the chemistry and pharmacology of nicotine, and adverse health consequences of smoking is provided as a background to better understand the use of pharmacological agents for smoking cessation.
Epidemiology
Cigarette smoking is the most popular method of using tobacco; other forms of smoking and tobacco use are summarized in Table 1.²⁻⁴ Worldwide, tobacco use causes more than 5 million deaths per year and if the current trends in the use of tobacco continue, it will cause 8 million deaths per year by 2030.⁴ Exposure to environmental tobacco smoke (ETS) results in an estimated 49,000 deaths every year.² Smoking and use of other forms of tobacco by youth is of particular significance, with 60% of new smokers being under the age of 18 when they first smoked a cigarette.

In 2007, more than 3 million American adolescents (aged 12–17) reported using a tobacco product in the month prior to the survey.² Tobacco use by adolescents is influenced by multiple psychosocial and biological factors that increase adolescents’ vulnerability for nicotine use.²,⁶,⁷ Studies show that adolescents are more sensitive to the reinforcing effects of nicotine and other chemicals found in cigarettes, further increasing their susceptibility to tobacco addiction. Intermittent smoking, such as over the weekends or at parties, has also been shown to result in tobacco addiction in adolescents. Tobacco use, especially the smokeless forms, is of special concern in athletes.⁴⁻¹⁵

Electronic cigarettes are a new trend and a major concern for young smokers.⁶,¹⁷ Electronic cigarettes are marketed to young smokers and are easily available over the internet and in shopping malls. The labeling on these cigarettes does not include the United States Food and Drug Administration (US FDA) warning of its harmful effects.¹⁶ Also called e-cigarettes, these are battery-operated devices that generally contain cartridges filled with nicotine, flavor and other chemicals. The electronic cigarette turns nicotine and other chemicals into vapor that is inhaled by the user. The US FDA has found that this form of cigarette is equally harmful, toxic, and addictive as other forms of tobacco use.¹⁶,¹⁷ In addition to various carcinogens, e-cigarettes also contain other chemicals such as diethylene glycol, which is an ingredient found in antifreeze liquid.¹⁶

Chemistry and pharmacology
Approximately 4,000 chemicals are found in the smoke of tobacco products, of which nicotine is primarily responsible for tobacco addiction.²,⁶,⁷ The chemistry and neuropharmacology of nicotine has been extensively studied.¹⁸⁻²¹ Other

Table 1 Main forms of tobacco used

| Cigarettes | Cigarette brands are categorized based on their tar content: |
|------------|----------------------------------------------------------|
|            | Ultra-light 1–6 mg tar                                    |
|            | Light 6–15 mg tar                                         |
|            | Full-flavor >15 mg tar                                    |
|            | Of all cigarettes sold in the United States, 84% are either light or ultra-light. Low-yield cigarettes and cigarette-like products are examples of a classification of products referred to as “potentially reduced-exposure products” (PREPs). |

| Cigars | Cigars contain the same toxic and carcinogenic compounds found in cigarettes. The three major types of cigars sold in the United States are large cigars, cigarillos, and little cigars. |

| Bidis | Bidis are small, thin hand-rolled cigarettes imported to the United States primarily from India and other Southeast Asian countries. They consist of tobacco wrapped in a tendu or temburni leaf (plants native to Asia), and may be secured with a colorful string at one or both ends. They have higher concentrations of nicotine, tar, and carbon monoxide than conventional cigarettes sold in the United States. |

| Kreteks | Kreteks (clove cigarettes) imported from Indonesia, typically contain a mixture consisting of tobacco, cloves, and other additives. Kreteks deliver more nicotine, carbon monoxide, and tar than conventional cigarettes. |

| Smokeless tobacco | Chewing tobacco comes in the form of loose leaf, plug, or twist. Snuff is finely ground tobacco that can be dry, moist, or in sachets (tea bag-like pouches). Although some forms of snuff can be used by sniffing or inhaling into the nose, most smokeless tobacco users place the product in their cheek or between their gum and cheek. Users then suck on the tobacco and spit out the tobacco juices, which is why smokeless tobacco is often referred to as spit or spitting tobacco. |

| Betel quid with tobacco (Gutka) | Gutka (ghustka or gutkha) is a dry, relatively nonperishable commercial preparation that consists of betel leaf (Piper betle), tobacco, areca nut (Areca catechu), catechu (extract of the Acaia catechu tree), and slaked lime (calcium hydroxide). Gutka is available in sachets and tins. It is consumed by placing a pinch of the mixture in the mouth between the gum and cheek and gently sucking and chewing. The excess saliva produced by chewing may be swallowed or spit out. Gutka is primarily consumed in the Indian subcontinent (India, Pakistan, and Bangladesh). In the Indian subcontinent, nonperishable, commercially manufactured preparations of betel quid without tobacco are known as pan masala, and freshly prepared betel quid (with or without tobacco) is known as pan. |

Based on data from: Centers for Disease Control and Prevention. Smoking and tobacco use: fact sheets. Available at http://www.cdc.gov/tobacco/data_statistics/fact_sheets. Accessed August 11, 2009.
main constituents of smoke that result in adverse health consequences include ammonia, benzene, carbon monoxide, cyanide, formaldehyde, acetaldehyde, phenols, and tar. Approximately 90% of the constituents of the smoke are in the form of vaporized chemicals, while rest are in the particulate form.\textsuperscript{,2,22}

Cigarettes are categorized (Table 1) based on their tar content (total particulate matter in smoke, excluding water and alkaloid compounds), which is measured using a standardized protocol on a smoking machine.\textsuperscript{2–4} In filtered cigarettes (99% of cigarettes currently on the market), the filter vents dilute the smoke with air, reducing standard yields of tar, nicotine, and carbon monoxide. Many smokers block the vents or compensate with increased inhalations when smoking low-yield cigarettes. By doing so, they typically get as much tar and nicotine from cigarettes with low-yield ratings as those with higher yields. On average a cigarette contains between 13–19 mg of nicotine; smoking 1 cigarette typically delivers 1–2 mg of nicotine.\textsuperscript{2,6,7} The nicotine content of tobacco smoke is 1%–2% and each inhalation delivers approximately 0.05–0.15 mg.\textsuperscript{2,7}

Smoke is produced by the incomplete combustion of tobacco. The fate of the cigarette smoke is depicted in Figure 1.\textsuperscript{22} Mainstream smoke—the smoke inhaled by the smoker directly through the mouthpiece of the cigarette—constitutes approximately 45% of the total smoke; whereas sidestream smoke, which is the smoke emitted by smoldering tobacco between puffs and the smoke diffusing through the lit cigarette paper and escaping from the burning cone during smoking, constitutes 55% of the total smoke.\textsuperscript{22}

Nicotine, whose chemical structure resembles that of the neurotransmitter acetylcholine, acts on stereospecific nicotinic cholinergic receptors (nAChRs) in the brain and other organs.\textsuperscript{7,21} The chemical structure and metabolic pathway of nicotine is depicted in Figure 2. It also has both direct and indirect effects on the neuroendocrine system. The initial phase of stimulation of the central nervous system (CNS) by nicotine is typically followed by a phase of CNS depression.\textsuperscript{7,20} The action of nicotine on nAChRs stimulates the release of various neurotransmitters and hormones including acetylcholine, norepinephrine, dopamine, vasopressin, serotonin, and beta-endorphins.\textsuperscript{2,6,7,19} Research shows that smoking is associated with a marked decrease in monoamine oxidase (MAO) levels in the brain.\textsuperscript{7} It is postulated that this decrease in MAO is caused by chemicals in the smoke other than nicotine. Decreased levels of MAO-A and MAO-B in the brain result in a higher level of dopamine. The action of nicotine on the CNS increases alertness, improves memory, improves concentration, and decreases anxiety. The pharmacokinetic properties of nicotine are summarized in Table 2.\textsuperscript{2,4,7,8,21}

**Effects on health**

The wide-ranging adverse effects of tobacco use have been well-established and well-documented.\textsuperscript{2,4,6,22–28} The numerous harmful health consequences of smoking are summarized in Table 3.
Nicotine activates reward pathways in the brain that regulate feelings of pleasure. These effects of nicotine are mediated by dopamine. Nicotine increases levels of dopamine mainly by its action on the mesolimbic dopamine system. Chronic use of nicotine results in an increase in the number of nicotine receptors in the brain. Consequently, more nicotine is required to achieve the desired effect, eventually resulting in tolerance and dependence. Regular tobacco use results in nicotine accumulation in the body, exposing the user to the effects of nicotine throughout the 24 hours. Nicotine levels in the brain and the associated feelings of pleasure and reward peak within 10 seconds of inhalation. However, the acute effects of nicotine dissipate rapidly. This causes the smoker to continue to smoke to maintain the effects of the nicotine and prevent withdrawal symptoms. The significant neurochemical changes in the brain that result from chronic nicotine use make it very difficult for the smoker to quit. Animal studies have shown that acetaldehyde, a chemical found in tobacco smoke, dramatically increases the reinforcing properties of nicotine and may also contribute to tobacco addiction. Adolescent animals show far more sensitivity to this reinforcing effect, suggesting increased vulnerability of adolescents to tobacco addiction.

Abrupt cessation of smoking results in withdrawal symptoms primarily due to decreased nicotine levels. Symptoms of nicotine withdrawal include: irritability; craving; depression; anxiety; cognitive and attention deficits; sleep disturbances; and increased appetite. The withdrawal symptoms, in most cases, begin within a few hours after the last cigarette, peak within the first few days of smoking cessation, and usually subside within a few weeks. In some cases, however the symptoms may persist for months.

### The role of behavioral approaches to smoking cessation

Behavioral treatment is integral to smoking cessation – studies have shown that a combination of behavioral and pharmacological treatment is more effective than either approach.
### Table 3 Adverse health effects of smoking and tobacco use

| Disease                        | Disease                        |
|--------------------------------|--------------------------------|
| **Cancer**                     | **Cancer**                     |
| • Bladder cancer               | • Bladder cancer               |
| • Cervical cancer              | • Cervical cancer              |
| • Esophageal cancer            | • Esophageal cancer            |
| • Kidney cancer                | • Kidney cancer                |
| • Laryngeal cancer             | • Laryngeal cancer             |
| • Leukemia                     | • Leukemia                     |
| • Lung cancer                  | • Lung cancer                  |
| • Oral cancer                  | • Oral cancer                  |
| • Pancreatic cancer            | • Pancreatic cancer            |
| • Stomach cancer               | • Stomach cancer               |
| **Cardiovascular diseases**    | **Cardiovascular diseases**    |
| • Abdominal aortic aneurysm    | • Abdominal aortic aneurysm    |
| • Acute and episodic increase in blood pressure | • Acute and episodic increase in blood pressure |
| • Acute increase in peripheral vascular resistance and blood pressure | • Acute increase in peripheral vascular resistance and blood pressure |
| • Atherosclerosis              | • Atherosclerosis              |
| • Cerebrovascular disease      | • Cerebrovascular disease      |
| • Coronary heart disease       | • Coronary heart disease       |
| • Decreased coronary blood flow (due to constriction of coronary arteries) | • Decreased coronary blood flow (due to constriction of coronary arteries) |
| • Decreased oxygen carrying capacity of the hemoglobin | • Decreased oxygen carrying capacity of the hemoglobin |
| • Hypertension                 | • Hypertension                 |
| • Increased baseline heart rate | • Increased baseline heart rate |
| • Increased oxygen demands of the myocardium (due to increased heart rate and blood pressure) | • Increased oxygen demands of the myocardium (due to increased heart rate and blood pressure) |
| • Increased risk for thromboembolism | • Increased risk for thromboembolism |
| • Increased risk of ventricular arrhythmias and sudden death (due to increased platelet adhesiveness, releasing catecholamines causing acute thrombosis and promoting ventricular arrhythmias) | • Increased risk of ventricular arrhythmias and sudden death (due to increased platelet adhesiveness, releasing catecholamines causing acute thrombosis and promoting ventricular arrhythmias) |
| • Peripheral vascular disease  | • Peripheral vascular disease  |
| **Respiratory diseases**       | **Respiratory diseases**       |
| • Bronchiolitis                | • Bronchiolitis                |
| • Bronchitis                   | • Bronchitis                   |
| • Chronic cough                | • Chronic cough                |
| • Chronic obstructive pulmonary disease | • Chronic obstructive pulmonary disease |
| • Decreased forced expiratory volume (FEV₁) | • Decreased forced expiratory volume (FEV₁) |
| • Decreased peak expiratory flow rate (PEFR) | • Decreased peak expiratory flow rate (PEFR) |
| • Development and exacerbation of asthma | • Development and exacerbation of asthma |
| • Dyspnea                      | • Dyspnea                      |
| • Eosinophilic granuloma       | • Eosinophilic granuloma       |
| • Halitosis                    | • Halitosis                    |
| • Hoarseness                   | • Hoarseness                   |
| • Idiopathic pulmonary fibrosis | • Idiopathic pulmonary fibrosis |
| • Impaired lung growth         | • Impaired lung growth         |
| • Impaired respiratory immunity | • Impaired respiratory immunity |
| • Increased respiratory allergies | • Increased respiratory allergies |
| • Interstitial lung disease    | • Interstitial lung disease    |
| • Laryngitis                   | • Laryngitis                   |
| • Ottis media and middle ear effusions | • Ottis media and middle ear effusions |
| **Cardiovascular diseases (Continued)** | **Cardiovascular diseases (Continued)** |
| **Reproductive effects**       | **Reproductive effects**       |
| • Fertility                    | • Fertility                    |
| • Fetal death and stillbirths  | • Fetal death and stillbirths  |
| • Low birth weight             | • Low birth weight             |
| • Pregnancy complications     | • Pregnancy complications     |
| • Premature menopause          | • Premature menopause          |
| **Musculoskeletal**            | **Musculoskeletal**            |
| • Decreased bone mineral density | • Decreased bone mineral density |
| • Increased risk for fractures | • Increased risk for fractures |
| • Increased spinal disk disease | • Increased spinal disk disease |
| **Gastrointestinal**           | **Gastrointestinal**           |
| • Decreased appetite           | • Decreased appetite           |
| • Gastroesophageal reflux disease | • Gastroesophageal reflux disease |
| • Impaired glucose tolerance   | • Impaired glucose tolerance   |
| • Increased insulin resistance | • Increased insulin resistance |
| • Peptic ulcer disease         | • Peptic ulcer disease         |
| **Mental health and psychosocial** | **Mental health and psychosocial** |
| • Addiction                    | • Addiction                    |
| • Anxiety, palpitations, tremors | • Anxiety, palpitations, tremors |
| • Nervousness, depression      | • Nervousness, depression      |
| • Tolerance and dependence     | • Tolerance and dependence     |
| • Withdrawal symptoms          | • Withdrawal symptoms          |
| **Effects on offspring of maternal smoking during pregnancy** | **Effects on offspring of maternal smoking during pregnancy** |
| • Certain childhood cancers    | • Certain childhood cancers    |
| • Increased cotinine in breastfed infants if mother smokes | • Increased cotinine in breastfed infants if mother smokes |
| • Increased incidence of conduct disorders | • Increased incidence of conduct disorders |
| • Increased probability of female children to be smokers | • Increased probability of female children to be smokers |
| • Low birth weight             | • Low birth weight             |
| • Miscarriage                  | • Miscarriage                  |
| • Prematurity                  | • Prematurity                  |
| • Sudden infant death syndrome | • Sudden infant death syndrome |
| **Specific effects of smokeless tobacco use** | **Specific effects of smokeless tobacco use** |
| • Excess salivation            | • Excess salivation            |
| • Gingivitis, gingival recession | • Gingivitis, gingival recession |
| • Halitosis                    | • Halitosis                    |
| • Leukoplakia                  | • Leukoplakia                  |
| • Oropharyngeal cancers        | • Oropharyngeal cancers        |
| • Periodontal disease          | • Periodontal disease          |
| • Staining of teeth            | • Staining of teeth            |
| **Other effects**              | **Other effects**              |
| • Altered lipid profile        | • Altered lipid profile        |
| • Altered metabolism of therapeutic drugs | • Altered metabolism of therapeutic drugs |
| • Anorexia and weight loss     | • Anorexia and weight loss     |
| • Cataracts                    | • Cataracts                    |
| • Decreased exercise performance | • Decreased exercise performance |
| • Diminished health status/increased morbidity | • Diminished health status/increased morbidity |
| • Esophagitis                  | • Esophagitis                  |
| • Gastroesophageal reflux disease | • Gastroesophageal reflux disease |
| • Hip fractures                | • Hip fractures                |
| • Low bone density             | • Low bone density             |

(Continued)
alone, \(^3,29–32\) Fiore and colleagues provide an extensive analysis of scientific evidence supporting the optimal efficacy of the combined behavioral and pharmacological approach for smoking cessation. The results of their meta-analysis of published studies indicate that providing counseling in addition to medication significantly enhanced treatment outcome – for medication alone the odds ratio (95% confidence interval [CI]) was 1.0, and estimated abstinence rate (95% CI) was 21.7, whereas for medication and counseling the estimated odds ratio (95% CI) was 1.4 (1.2–1.6), and estimated abstinence rate (95% CI) was 27.6 (25.0–30.3). \(^3\) Conversely, Fiore and colleagues also found that providing medication in addition to counseling also significantly enhanced treatment outcome – for counseling alone the estimated odds ratio (95% CI) was 1, and estimated abstinence rate (95% CI) was 14.6, whereas for medication and counseling the estimated odds ratio (95% CI) was 1.7 (1.3–2.1) and the estimated abstinence rate (955 CI) was 22.1 (18.1–26.8). \(^3\)

In addition to the neurochemical effects of nicotine, behavioral factors also affect the severity of nicotine withdrawal symptoms. For some people, the feel, smell, and sight of a cigarette and the ritual of obtaining, handling, lighting, and smoking a cigarette are all associated with the pleasurable effects of smoking. Consequently, this can worsen withdrawal symptoms or cravings. Behavioral therapies can help smokers identify environmental triggers of craving so they can employ strategies to prevent or circumvent these symptoms and urges. It is important to recognize that smoking cessation is a team effort. The social setting in which smoking occurs, the social culture of the smoker, and the support networks available to the smoker, all play critical role in the success of smoking cessation by the smoker. Among the professionals, the pharmacist plays a critical role in providing ongoing support, education, and counseling.

### Pharmacological agents

General factors, which should to be considered when prescribing pharmaceutical agents for smoking cessation, are summarized in Table 4. Patients who smoke may be on therapeutic drugs for other chronic diseases. The effective dosages of these therapeutic drugs reflect the adjustments made because of concomitant exposure to nicotine. With smoking cessation and elimination of nicotine from the body, a new state of metabolic homeostasis will result that may necessitate adjusting dosage of therapeutic drugs. Drug-drug interactions are an important consideration when using pharmacotherapy for smoking cessation, especially in smokers who are on other medications for chronic diseases. Smoking induces some isoforms of the hepatic cytochrome P450. \(^1\) Nicotine, although metabolized by CYP2A6, is not a significant inducer of CYP enzymes. \(^3\) Therefore, when smoker quits with or without being on nicotine replacement therapy, the baseline functioning of the P450 enzyme system is restored, and can increase the serum levels of certain drugs (eg, fluvoxamine, olanzepine, clozapine), resulting in their increased side-effects. \(^3\) Nicotine replacement therapy may reduce the sedative effects of benzodiazepines, subcutaneous absorption of insulin, and the blood pressure lowering effect of some beta-blockers. \(^2\) Some drugs reported to have significant interactions with bupropion include: cyclophosphamide; orphenadrine; tricyclic antidepressants; antipsychotics; certain antiarrhythmic drugs; certain beta-blockers; carbamazepine; phenytoin; phenobarbital; valproate; and cimetidine. \(^3\) Varenicline is not reported to have specific significant drug-drug interactions.

Tobacco dependence should be considered a chronic disease and as such its management requires on-going patient education, counseling, and use of medications as indicated. \(^3\) Relapses are common during smoking cessation and patients require long-term monitoring and treatment. Long-term pharmacotherapy, combination therapy, and re-use of drugs previously used (recycling) should be considered in relapse prevention and treatment. In some patients who are not able to quit completely, pharmacotherapy has been used to reduce smoking, with some achieving a 50% reduction in smoking. \(^3,7\) With pharmacotherapy, the estimated 6-month abstinence rate is about 20%, compared to approximately 10% without pharmacotherapy. \(^3,6,7\) All pharmacologic agents have been shown to be effective in smoking cessation with odds ratios between two and four when compared to placebo treatment. \(^3,6\) Absolute smoking cessation rates vary depending on the particular pharmacologic agent used and the intensity of concomitant counseling; rates vary in range from 5% to 35%. \(^3,6,7\) The smoker’s

### Table 3 (Continued)

| Disease                          |
|---------------------------------|
| - Macular degeneration          |
| - Nicotine addiction (tolerance dependence, withdrawal symptoms) |
| - Osteoporosis                  |
| - Peptic ulcer disease          |
| - Spinal disk disease           |

**Sources:** U.S. Department of Health Education, and Welfare 1964, 1967, 1979; U.S. Department of Health and Human Services 1980, 1982, 1983, 1984, 1989, 1990, 1994, 2001. Data from: (1) U.S. Department of Health and Human Services: The Health Consequences of Smoking. Nicotine Addiction: A Report of the Surgeon General. Washington, DC, 1988 U.S. Department of Health and Human Services; (2) The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health, 2004. Available at http://www.cdc.gov/tobacco/data_statistics/sgr_2004/index.htm. Accessed August 11, 2009.
Combining the nicotine patch long-term has been shown to be effective in highly dependent smokers. Combination nicotine replacement therapy (NRT) may be particularly effective in suppressing tobacco withdrawal symptoms. NRT combinations are especially helpful for highly dependent smokers or those with a history of severe withdrawal.

Bupropion SR and nortriptyline appear to be effective, but nicotine replacement medications also appear to help individuals with a history of depression.

Health insurance coverage, out-of-pocket costs, likelihood of adherence, dentures when considering the gums, or dermatitis when considering the patch.

Prior successful experience (sustained abstinence with the medication) suggests that the medication may be helpful to the patient in a subsequent quit attempt, especially if the patient found the medication to be tolerable and or easy to use. However, it is difficult to draw firm conclusions from prior failure with a medication.

Consider the importance of smoker's social setting, social culture, and support networks. These and other environmental factors play important role in the success of any smoking cessation strategy.

The higher-dose preparations of nicotine gum, patch, and lozenge have been shown to be effective in highly dependent smokers. Combination nicotine replacement therapy (NRT) may be particularly effective in suppressing tobacco withdrawal symptoms. NRT combinations are especially helpful for highly dependent smokers or those with a history of severe withdrawal.

Cessation medications generally not beneficial to light smokers. If NRT is used with light smokers, consider reducing the dose of the medication. No adjustments are necessary when using bupropion SR or varenicline.

NRT can be effective with both sexes; however, evidence is mixed as to whether NRT is less effective in women than men. This may encourage the clinician to consider use of another type of medication with women, such as bupropion SR or varenicline.

Bupropion SR and nicotine replacement therapies, in particular 4-mg nicotine gum and 4-mg nicotine lozenge, delay – but do not prevent – weight gain.

Bupropion SR and nortriptyline appear to be effective, but nicotine replacement medications also appear to help individuals with a history of depression.

The nicotine patch has been demonstrated safe for patients with a history of cardiovascular disease.

Long-term use is helpful with smokers who report persistent withdrawal symptoms during the course of medications, who have relapsed in the past after stopping medication, or who desire long-term therapy. A minority of individuals who successfully quit smoking use ad libitum NRT medications (gum, nasal spray, inhaler) long-term. The use of these medications for up to 6 months does not present a known health risk and developing dependence on medications is uncommon. The FDA has approved the use of bupropion SR, varenicline, and some NRT medications for 6-month use.

Combining the nicotine patch long-term (>14 weeks) with nicotine gum or nicotine nasal spray, the nicotine patch with the nicotine inhaler, or the nicotine patch with bupropion SR, increases long-term abstinence rates relative to placebo treatments. Combining varenicline with NRT agents has been associated with higher rates of side effects (eg, nausea, headaches).

The first-line drugs for smoking cessation approved by the FDA are varenicline, bupropion sustained release (SR), and nicotine replacement drugs. These drugs are approved by the FDA for use in adults. Data are insufficient to assess their efficacy in adolescents. Pharmacotherapy has not been shown to be effective in light smokers and in those who use smokeless tobacco.

Varenicline

Varenicline acts by selective binding at α4β2 neuronal nicotinic acetylcholine receptors, which results in agonist activity, while simultaneously preventing nicotine binding to α4β2 receptors. The FDA recommendation for varenicline product label includes a warning that serious neuropsychiatric symptoms have been reported in patients being treated with this drug. Varenicline, therefore, should preferably be avoided in persons who have a history of neuropsychiatric disorders. It is not uncommon for patients to experience feelings of depression, anxiety, irritability, and sleep disturbances during smoking cessation. Although some of these symptoms may be associated with nicotine withdrawal, symptoms have occurred in patients who continued to smoke. Patients on varenicline should be monitored for agitation, depressed mood, and changes in behavior that are not typical for the patient. The patient also must be assessed for suicidal ideation or suicidal behavior. Varenicline is
Disadvantages: Not studied in combination with other therapies, nausea associated with higher doses may be bothersome, does not reduce weight gain, may cause impaired ability to drive or operate heavy machinery, may cause neuropsychiatric symptoms including behavioral changes, agitation, depressed mood, suicidal ideation, and suicidal behavior.

Table 5 Vareniclineab

| Product   | Chantix® (Pfizer, Inc., New York City, NY) |
|-----------|--------------------------------------------|
| Precautions | • Pregnancy                                |
|           | • May worsen pre-existing psychiatric illness |
|           | • Dosage adjustment required in patients with kidney disease (creatinine clearance less than 30 ml/min) or who are on dialysis |
|           | • WARNING: Can cause depressed mood, agitation, change in behavior, suicidal ideation, suicide. Reported in patients attempting to quit smoking while using varenicline. Monitor closely. |

Dosage: Recommended: 1-week titration:

- Days 1–3: 0.5 mg tablet daily
- Days 4–7: 0.5 mg tablet BID (AM and HS)
- Days 8+: 1 mg tablet BID (AM and HS)

- Set quit date
- Start one week before quit date
- Take after eating and with a full glass of water
- Nausea is dose related; if persistent and troubling, consider dose reduction. Duration: 12 wk; if successful after 12 week, an additional 12 week is recommended for increased likelihood of long-term abstinence

Side effects:

- Dose dependent nausea (most common)
- Insomnia
- Abnormal dreams
- Headache
- Dyspepsia
- Constipation
- Flatulence
- Vomiting

Advantages:

- Provides nicotine effects to reduce withdrawal symptoms and cravings
- Blocks the nicotine effects from smoking and reduces reward of smoking
- May be used in those with cardiovascular disease
- No clinically meaningful drug interactions
- Found to be more effective than bupropion SR

Disadvantages:

- Also carries an FDA warning for neuropsychiatric adverse events. Bupropion lowers the seizure threshold and is contraindicated in persons with a history of seizure disorder and those who are on other medications that lower the seizure threshold. It is also contraindicated in persons who have a prior or current history of eating disorder because of an increased risk for seizures. Bupropion SR is also an anti-depressant and like other anti-depressant drugs, it carries a warning for increased risk of suicidal ideation. Patients on bupropion should therefore be closely monitored for emerging neuropsychiatric symptoms and signs of suicidal ideation. Prescribing information for bupropion SR for smoking cessation is summarized in Table 6.

Table 6 Bupropion SRab

| Product   | Zyban® (GlaxoSmithKline plc, Brentford, London, England, UK), Generic |
|-----------|---------------------------------------------------------------------|
| Contraindications | • History of seizure disorder                                  |
|           | • History of stroke                                                |
|           | • History of brain tumor; brain surgery, or serious closed head injury |
|           | • Eating disorders                                                 |
|           | • Those taking another form of bupropion                           |
|           | •Monoamine oxidase inhibitor therapy within previous 14 d          |
|           | • Abrupt discontinuation of alcohol or benzodiazepines at same time |

Precautions:

- Pregnancy
- Concomitant therapy with medications known to lower the seizure threshold

Dosage: 150 mg PO q AM × 3 d, then increase to 150 mg PO BID

- Treatment should be initiated while patient is still smoking
- Set quit date 1–2 weeks after initiation
- DO NOT exceed 300 mg/d
- Allow at least 8 h between doses
- Avoid bedtime dosing to minimize insomnia
- May be used safely with NRT
- If progression towards abstinence unsuccessful by week 7, discontinue

Side effects:

- Insomnia most common (35%–40%)
- Dry mouth
- Nervousness
- Agitation
- Anxiety
- Weight loss
- Constipation
- Seizures (risk is 1/1000)

Advantages:

- Bupropion can be safely used with NRT
- Bupropion may be beneficial in patients with depression
- No tapering required

Disadvantages:

- Seizure risk is increased
- May increase the risk of suicidal thinking in patients who have depression

It is also

Bupropion SR is also an anti-depressant and like other anti-depressant drugs, it carries a warning for increased risk of suicidal ideation. Patients on bupropion should therefore be closely monitored for emerging neuropsychiatric symptoms and signs of suicidal ideation. Prescribing information for bupropion SR for smoking cessation is summarized in Table 6.

Table 6 Bupropion SRab

| Product   | Zyban® (GlaxoSmithKline plc, Brentford, London, England, UK), Generic |
|-----------|---------------------------------------------------------------------|
| Contraindications | • History of seizure disorder                                  |
|           | • History of stroke                                                |
|           | • History of brain tumor; brain surgery, or serious closed head injury |
|           | • Eating disorders                                                 |
|           | • Those taking another form of bupropion                           |
|           | •Monoamine oxidase inhibitor therapy within previous 14 d          |
|           | • Abrupt discontinuation of alcohol or benzodiazepines at same time |

Precautions:

- Pregnancy
- Concomitant therapy with medications known to lower the seizure threshold

Dosage: 150 mg PO q AM × 3 d, then increase to 150 mg PO BID

- Treatment should be initiated while patient is still smoking
- Set quit date 1–2 weeks after initiation
- DO NOT exceed 300 mg/d
- Allow at least 8 h between doses
- Avoid bedtime dosing to minimize insomnia
- Can be used safely with NRT
- If progression towards abstinence unsuccessful by week 7, discontinue

Side effects:

- Insomnia most common (35%–40%)
- Dry mouth
- Nervousness
- Agitation
- Anxiety
- Weight loss
- Constipation
- Seizures (risk is 1/1000)

Advantages:

- Bupropion can be safely used with NRT
- Bupropion may be beneficial in patients with depression
- No tapering required

Disadvantages:

- Seizure risk is increased
- May increase the risk of suicidal thinking in patients who have depression

It is also

Bupropion SR is also an anti-depressant and like other anti-depressant drugs, it carries a warning for increased risk of suicidal ideation. Patients on bupropion should therefore be closely monitored for emerging neuropsychiatric symptoms and signs of suicidal ideation. Prescribing information for bupropion SR for smoking cessation is summarized in Table 6.

Table 6 Bupropion SRab

| Product   | Zyban® (GlaxoSmithKline plc, Brentford, London, England, UK), Generic |
|-----------|---------------------------------------------------------------------|
| Contraindications | • History of seizure disorder                                  |
|           | • History of stroke                                                |
|           | • History of brain tumor; brain surgery, or serious closed head injury |
|           | • Eating disorders                                                 |
|           | • Those taking another form of bupropion                           |
|           | •Monoamine oxidase inhibitor therapy within previous 14 d          |
|           | • Abrupt discontinuation of alcohol or benzodiazepines at same time |

Precautions:

- Pregnancy
- Concomitant therapy with medications known to lower the seizure threshold

Dosage: 150 mg PO q AM × 3 d, then increase to 150 mg PO BID

- Treatment should be initiated while patient is still smoking
- Set quit date 1–2 weeks after initiation
- DO NOT exceed 300 mg/d
- Allow at least 8 h between doses
- Avoid bedtime dosing to minimize insomnia
- Can be used safely with NRT
- If progression towards abstinence unsuccessful by week 7, discontinue

Side effects:

- Insomnia most common (35%–40%)
- Dry mouth
- Nervousness
- Agitation
- Anxiety
- Weight loss
- Constipation
- Seizures (risk is 1/1000)

Advantages:

- Bupropion can be safely used with NRT
- Bupropion may be beneficial in patients with depression
- No tapering required

Disadvantages:

- Seizure risk is increased
- May increase the risk of suicidal thinking in patients who have depression

It is also

Bupropion SR is also an anti-depressant and like other anti-depressant drugs, it carries a warning for increased risk of suicidal ideation. Patients on bupropion should therefore be closely monitored for emerging neuropsychiatric symptoms and signs of suicidal ideation. Prescribing information for bupropion SR for smoking cessation is summarized in Table 6.
Nicotine replacement therapies

Nicotine replacement therapy (NRT) drugs reduce craving and withdrawal symptoms by partially replacing lost nicotine intake. The main characteristics and prescribing information of available NRT products are summarized in Tables 7 through Table 11.3,29,33–35,43,44

Second-line medications

Clonidine and nortriptyline are second-line medications used for smoking cessation.3,45 Although second-line medications have been shown to be effective in treating tobacco dependence, their use is limited mainly because of less favorable side-effect profile when compared to the first-line medications. Second-line medications are not approved by the FDA specifically for use in smoking cessation.3 Second-line medications should be considered for use on a case-by-case basis after first-line medications (either alone or in combination) have been used without success, or are contraindicated.3

Clonidine is contraindicated in pregnant women and in those who engage in potentially hazardous activities. The most common side effects of clonidine include dry mouth (40%), drowsiness (33%), dizziness (16%), sedation (10%) and constipation (10%).3 Because abrupt discontinuation of clonidine can result in severe rebound hypertension, it should be tapered. Clonidine is available as 0.1 mg, 0.2 mg, and 0.3 mg scored tablets and 0.1 mg/24 hours, 0.2 mg/24 hours, and 0.3 mg/24 hours transdermal patches. The usual dosage is 0.2 mg–0.6 mg per day in divided doses.3,45 Specific dosage of clonidine for smoking cessation has not been established.

Nortriptyline is a tricyclic antidepressant and therefore carries an FDA warning about increased suicide risk.3 The most serious side effects of nortriptyline are arrhythmias and impairment of myocardial contractility. More common and less serious side effects include sedation, dry mouth, blurred vision, urinary retention, lightheadedness, and shaky hands.3 Nortriptyline is available as 10 mg, 25 mg, 50 mg, and 75 mg capsules and 10 mg/5 mL liquid. The dosage of

| Products | Nicotrol Patch® (McNeil Consumer Healthcare, Fort Washington, PA) | Nicoderm® CQ (Sanofi-Aventis S.A., Paris, France); Generic nicotine patch |
|----------|---------------------------------------------------------------|-------------------------------------------------------------------------|
| Dosage   | • >10 cigarettes/day                                           | • >10 cigarettes/day |
|          | • ≥10 cigarettes/day                                          | • ≤10 cigarettes/day |
|          | • 5 mg                                                        | • 5 mg |
|          | • 10 mg, 15 mg (16 hours)                                     | • 10 mg/24 hours |
|          | • 15 mg/day × 6 week                                          | • 14 mg/day × 6 week |
|          | • 10 mg/day × 2 week                                          | • 14 mg/day × 2 week |
|          | • 5 mg/day × 2 week                                           | • 7 mg/day × 2 weeks |
|          | • If <100 lbs or cardiovascular disease:                       | • If <100 lbs or cardiovascular disease: |
|          | • 14 mg/day × 4–6 week                                         | • 14 mg/day × 4–6 week |
|          | • 7 mg/day × 2–4 week                                          | • 7 mg/day × 2–4 week |

Comments3

• Remove before bedtime
• Nicotine released over 16 h
• May wear patch for 24 h
• Remove at bedtime if patient experiences sleep disturbances.

Contraindications

• Pregnancy
• Recent (2 or less week post-myocardial infarction)
• Unstable angina pectoris
• Serious underlying arrhythmias

Side effects

• Local skin reactions: erythema, pruritis, burning
• Headache
• Sleep disturbances: insomnia, vivid dreams

Advantages

• Provides consistent nicotine levels over 16–24 hours
• Easy to use and conceal
• Fewer adherence issues
• Available without prescription

Disadvantages

• Patients cannot titrate the dose
• Allergic reactions to adhesive
• Patients with certain skin conditions cannot use patch
• Patch may contain aluminum

Notes: 3Patch should be applied in the morning when patient wakes on the quit day. Apply on relatively hairless areas between the neck and waist.
nortriptyline in smoking cessation studies ranges between 25 mg per day and 100 mg per day.\textsuperscript{3,4,5,6} Therapeutic drug level and cardiovascular monitoring, including electrocardiogram (ECG), is recommended.

Several investigators have reported on the use of iontophoresis and chemical enhancers to deliver nortriptyline.

### Table 8 Gum\textsuperscript{OTC}

| Product | Nicorette\textsuperscript{®} (GlaxoSmithKline plc, Brentford, London, England, UK), Nicorette DS\textsuperscript{®} (GlaxoSmithKline plc, Brentford, London, England, UK), Generic |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contraindications | • Pregnancy  
• Recent (\textleq; 2 weeks) myocardial infarction  
• Serious underlying arrhythmias  
• Serious or worsening angina pectoris  
• Temporomandibular joint disease |
| Dosage | ≥25 cigarettes/day: 4 mg  
<25 cigarettes/day: 2 mg  
• Week 1–6: 1 piece q 1–2 hours  
• Week 2–4: 1 piece q 2–4 hours  
• Week 10–12: 1 piece q 4–8 hours |
| Side effects | • Mouth soreness  
• Throat irritation  
• Jaw pain  
• Hiccups  
• Dyspepsia  
• Hypersalivation  
• Flatulence  
• Nausea and vomiting  
• Unpleasant taste  
• Lightheadedness |
| Advantages | • Might satisfy oral cravings  
• May delay weight gain  
• Patients can titrate therapy to manage withdrawal symptoms  
• Available over the counter |
| Disadvantages | • Gum chewing may not be socially acceptable  
• Difficult to use with dentures  
• May cause loosening of dental fillings  
• Patients must use proper chewing technique to minimize adverse effects |

### Table 9 Lozenge\textsuperscript{OTC}

| Product | Commit\textsuperscript{®} (GlaxoSmithKline plc, Brentford, London, England, UK) |
|---------|-----------------------------------------------------------------------------|
| Contraindications | • Pregnancy  
• Recent (\textleq; 2 weeks) myocardial infarction  
• Serious underlying arrhythmias  
• Serious or worsening angina pectoris |
| Dosage | 1st cigarette ≤30 min after waking up: 4 mg  
1st cigarette >30 min after waking up: 2 mg  
• Week 1–6: 1 lozenge q 1–2 hours; minimum 9 per day  
• Week 7–9: 1 lozenge q 2–4 hours  
• Week 10–12: 1 lozenge q 4–8 hours |
| Adverse events | • Nausea  
• Hiccups  
• Cough  
• Heartburn  
• Headache |

Advantages

- Might satisfy oral cravings
- May delay weight gain
- Patients can titrate therapy to manage withdrawal symptoms
- Provides ~25% more nicotine than gum
- Available over the counter

Disadvantages

- Gastrointestinal side effects might be bothersome
- Contains phenylalanine

They noted that the highest flux obtained would provide the recommended doses for smoking cessation support therapy (25–75 mg) with a 2 cm × 2 cm patch or 3.5 cm × 3.5 cm patch, respectively, without skin damage.\textsuperscript{48} Merino and
colleagues reported on the use of chemical enhancers and iontophoresis to enhance transdermal delivery of nortriptyline. They also noted that iontophoresis could be used to provide therapeutic concentrations of the drug in smoking cessation treatment.

## Conclusion

Tobacco use remains a great public health concern, especially in adolescents. The significant health hazards of smoking and other forms of tobacco use are well-documented. Smoking can also adversely affect exercise and sports performance. Tobacco addiction is primarily caused by nicotine, though other chemicals contained within tobacco products are now believed to play a secondary role in addiction. A combined behavioral and pharmacological approach has been found to be more effective for smoking cessation than either approach used alone. The importance of team effort in any smoking cessation strategy should be recognized. The environmental factors and public policies play important roles in population wide smoking cessation efforts. Considerable evidence supports the role of the pharmacist in the management of chronic diseases, including smoking cessation. To decrease the overall burden of smoking, all healthcare practitioners need to work together. A range of pharmacological agents and behavioral therapies are available for smoking cessation.

### Table 10 Nasal spray<sup>α</sup>

| Product     | Nicotrol NS<sup>®</sup> (Pfizer, Inc., New York City, NY) |
|-------------|---------------------------------------------------------|
|             | Metered spray (0.5 mg nicotine/actuation) aqueous nicotine |
| Contraindications | Pregnancy |
|              | Recent (<=2 weeks) myocardial infarction |
|              | Serious underlying arrhythmias |
|              | Serious or worsening angina pectoris |
| Dosage      | 1–2 doses/h (8–40 doses/day) |
|             | One dose: 2 sprays (one in each nostril); each spray delivers 0.5 mg of nicotine to the nasal mucosa |
|             | Patients should not sniff, swallow, or inhale through the nose as the spray is administered |
|             | For best results, initially use at least 8 doses/day |
|             | DO NOT exceed 5 doses/hours and 40 doses/day |
|             | Gradually decrease usage |
| Duration (maximal): | 3 month |
| Side effects | Nasal and throat irritation (hot, peppery, or burning sensation) |
|              | Transient change in sense of smell and taste |
|              | Rhinitis |
|              | Tearing |
|              | Sneezing |
|              | Cough |
|              | Headache |
|              | Nausea |
| Advantages   | Patients can easily titrate therapy to rapidly manage withdrawal symptoms |
|              | Fastest acting nicotine product |
| Disadvantages | Nasal/throat irritation may be bothersome |
|              | Dependence can result |
|              | Patients must wait 5 minutes before driving or operating heavy machinery |
|              | Patients with chronic nasal disorders (allergy, rhinitis, nasal polyps, or sinusitis) or severe reactive airway disease should NOT use the spray |
|              | No optimal tapering schedule |
|              | Prescription only |

### Table 11 Oral inhaler<sup>α</sup>

| Product     | Nicotrol Inhaler<sup>®</sup> (Pfizer, Inc., New York City, NY) |
|-------------|---------------------------------------------------------------|
|             | 10 mg cartridge delivers 4 mg inhaled nicotine vapor |
| Contraindications | Pregnancy |
|              | Recent (<=2 weeks) myocardial infarction |
|              | Serious underlying arrhythmias |
|              | Serious or worsening angina pectoris |
| Dosage      | 6–16 cartridges/d; individualize dosing |
|             | Initially, use at least 6 cartridges/d for first 3–6 week |
|             | Best effects with continuous puffing for 20 minutes |
|             | Nicotine in cartridge is depleted after 20 minutes of active puffing (oral inhalation) |
|             | Patients should inhale deeply into back of throat or puff in short breaths |
|             | Open cartridge retains potency for 24 hours |
|             | Each cartridge delivers 4 mg of nicotine over 80 inhalations |
|             | Avoid eating or drinking for 15 minutes before and after use (acidic beverages reduce absorption) |
| Duration: | Treat for 3 month and then taper over next 3 month |
| Adverse events | Mouth and throat irritation (40%) |
|              | Unpleasant taste |
|              | Cough (32%) |
|              | Rhinitis (23%) |
|              | Dyspepsia |
|              | Headache |
| Advantages   | Patients can easily titrate therapy to rapidly manage withdrawal symptoms |
|              | The inhaler mimics hand-to-mouth ritual of smoking |
| Disadvantages | Initial throat or mouth irritation can be bothersome |
|              | Dependence can occur |
|              | Cold temperatures (<60°F) reduce amount of nicotine delivered |
|              | Avoid hot environments (>77°F) and protect from light |
|              | Patients with underlying bronchospastic disease must use with caution |
|              | No definitive tapering schedule |
|              | Prescription only |
Varenicline, bupropion SR, and nicotine replacement therapies are recommended as first-line drugs for smoking cessation. In selected cases the first-line drugs may also be used in combination with each other to improve outcomes. Treatment interventions have been shown to double the rate of smoking cessation when compared to quit attempts without intervention. Tobacco dependence should be considered a chronic disease with anticipated relapses requiring long-term monitoring and treatment.

Acknowledgments
Authors thank Kim Douglas for assistance with the preparation of this manuscript. Data in Table 5 to Table 11 are derived from: 1) Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence 2008 Update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service. May 2008; 2) Food and Drug Administration product information available at www.fda.gov; 3) Drug manufacturer product labels available at manufacturer web sites; including following web sites:

- Chantix http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021928s007lbl.pdf; Zyan http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm176815.htm; Nicotrol inhaler http://media.pfizer.com/files/products/uspi_nicotrol_inhaler.pdf; Nicotrol NS http://media.pfizer.com/files/products/uspi_nicotrol.pdf; Nicoderm CQ http://www.nicodermcq.com; Commit http://www.commitlozenge.com; Nicorette http://www.nicorette.com/

Disclosures
The authors report no conflicts of interest that are relevant to this research.

References
1. Britannica.com (Encyclopaedia Britannica). http://www.britannica.com. Accessed August 16, 2009.
2. Centers for Disease Control and Prevention. Smoking and tobacco use: fact sheets. Available at http://www.cdc.gov/tobacco/data_statistics/fact_sheets. Accessed August 11, 2009.
3. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence 2008 Update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service; 2008.
4. US Department of Health and Human Services. National Institute of on Drug Abuse. Research Report Series: Tobacco Addiction. Available from: http://www.nida.nih.gov/researchreports/nicotine/nicotine.html. Accessed August 17, 2009.
5. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008. Geneva, Switzerland: WHO; 2008.
6. Hatsuoki DM, Stead LF, Gupta PC. Tobacco addiction. Lancet. 2008;371(9629):2027–2038.
7. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49:57–71.
8. Walsh MM, Ellison J, Hilton JF, Chesney M, Ennister VL. Spit (smokeless) tobacco use by high school baseball athletes in California. Tob Control. 2009;9 Suppl 2:i32–i39.
9. Melnick MJ, Miller KE, Sabo DF, Farrell MP, Barnes GM. Tobacco use among high school athletes and nonathletes: results of the 1997 youth risk behavior survey. Adolesc Med. 2001;36(144):727–747.
10. Green GA, Uryasz FD, Petr TA, Bray CD. NCAA study of substance use and abuse habits of college student-athletes. Clin J Sport Med. 2001;11(1):51–56.
11. Alaranta A, Alaranta H, Patjakka K, Palmu P, Prättälä R, Martelin T, Heleinius I. Snuff use and smoking in Finnish Olympic athletes. Int J Sports Med. 2006;27(7):581–586.
12. Peretti-Watel P, Guagliardo V, Verger P, Pruvost I, Mignon P, Obadia Y. Sporting activity and drug use: alcohol, cigarette and cannabis use among elite student athletes. Addiction. 2003;98(9):1249–1256.
13. Walsh MM, Hilton JF, Ennister VL, Masouredis CM, Grady DG. Prevalence, patterns, and correlates of spit tobacco use in a college athlete population. Addict Behav. 1994;19(4):411–427.
14. Davis TC, Arnold C, Nandy I, Bocchini JA, Gottlieb A, George RB, Berkel H. Tobacco use among male high school athletes. J Adolesc Health. 1997;21(2):97–101.
15. Epps RP, Lynn WR, Manley MW. Tobacco, youth, and sports. Adolesc Med. 1998;9(3):483–490.
16. United State Food and Drug Administration. Electronic cigarettes. Available from: http://www.fda.gov. Accessed January 1, 2010.
17. Wollinscheidt KA, Kremzner ME. Electronic cigarettes: safety concerns and regulatory issues. Am J Health Sys Pharm. 2009;66(19):1740–1742.
18. Fletcher PJ, Lê AD, Higgins GA. Serotonin receptors as potential targets for modulation of nicotine use and dependence. Prog Brain Res. 2008;172:361–383.
19. Gamberino WC, Gold MS. Neurobiology of tobacco smoking and other addictive disorders. Psychiatric Clin North Am. 1999;22:301–312.
20. Rose JE. Disrupting nicotine reinforcement: from cigarette to brain. Ann N Y Acad Sci. 2008;1141:233–256.
21. Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia. In: Hardman JG, Limbird LE, editors. Goodman Gilman’s The Pharmacologic Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996. p. 177–198.
22. US Department of Health and Human Services. The Health Consequences of Smoking. Nicotine Addiction: A Report of the Surgeon General. Washington, DC; US Department of Health and Human Services; 1988.
23. Aubry M, Wright JL, Myers JL. The pathology of smoking-related diseases. Clin Chest Med. 2000;21:11–35.
24. Fiore MC, Pisecke TH, Baker LJ, Decren SM. Cigarette smoking: the leading preventable cause of pulmonary disease. In: Bone RC, editors. Pulmonary and Critical Care Medicine. St. Louis, Mosby MO: 1998.
25. Patel DR, Homnick DN. Pulmonary effects of smoking. Clin Chest Med. 2000;11:547–565.
26. Sethi JM, Rochester C1. Smoking and chronic obstructive pulmonary disease. Clin Chest Med. 2000;21(1):67–86.
27. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health; 2004. Available from http://www.cdc.gov/tobacco/data_statistics/sgr/sgr_2004/index.htm. Accessed August 11, 2009.
28. US Department of Health and Human Services. The Health Benefits of Smoking Cessation: A Report of the Surgeon General, 1990 Washington, DC; US Department of Health and Human Services. Available from http://www.cdc.gov/tobacco/data_statistics/sgr/index.htm.
29. Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 3 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med. 2009;169(22):2148–2155.
30. Lemmens V, Oenema A, Knut IK, Brug J. Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. *Eur J Cancer Prev*. 2008;17(6):535–544.
31. Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. *Clin Ther*. 2009;31(3):463–491.
32. Shah SD, Wilken LA, Winkler SR, Lin SJ. Systematic review and meta-analysis of combination therapy for smoking cessation. *J Am Pharm Assoc*. 2008;48(5):659–665.
33. Carrozzli L, Pistelli F, Vieggi G. Pharmacotherapy for smoking cessation. *Ther Adv Respir Dis*. 2008;2(5):301–317.
34. Eisenberg MJ, Filion KB, Yavind D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. *CMAJ*. 2008;179(2):135–144. Review. Erratum in: *CMAJ*. 2008;179(8):802.
35. Fant RV, Buchhalter AR, Buchman AC, Henningfield JE. Pharmacotherapy for tobacco dependence. *Handb Exp Pharmacol*. 2009;192:487–510.
36. The Medical Letter: Drugs for tobacco dependence. *Treatment Guidelines The Medical Letter*. 2008;6(73):61–66.
37. Hajeck P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation. *Cochrane Database Syst Rev*. 2009(1):CD003999.
38. Galanti LM. Tobacco smoking cessation management: integrating varenicline in current practice. *Vasc Health Risk Manag*. 2008;4(4):837–845.
39. Garrison GD, Dugan SE. Varenicline: a first-line treatment option of smoking cessation. *Clin Ther*. 2009;31(3):463–491.
40. Hays JT, Ebbert JO. Varenicline for tobacco dependence. *N Engl J Med*. 2008;359(19):2018–2024.
41. Lee JH, Jones PG, Bybee K, O’Keefe JH. A longer course of varenicline therapy improves smoking cessation rates. *Prev Cardiol*. 2008;11(4):210–214.
42. Paterson NE. Behavioural and pharmacological mechanisms of bupropion’s anti-smoking effects: recent preclinical and clinical insights. *Eur J Pharmacol*. 2009;603(1–3):1–11. Epub 2008 Dec 16.
43. Walsh RA. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. *Drug Alcohol Rev*. 2008;27(5):529–547.
44. Amodei N, Lamb R. Over-the-counter nicotine replacement therapy: can its impact on smoking cessation be enhanced? *Psychol Addict Behav*. 2008;22(4):472–485.
45. Stahl SM. Essential Psychopharmacology: A Prescriber’s Guide, New York; Cambridge University Press, 2006. p. 53–58. p. 353–360.
46. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev*. 2007;24(1):CD000311.
47. Escobar-Chavez JJ, Merino V, Lopez-Cervantes M, Rodriguez-Cruz IM, Quintanar-Guerrero D, Ganem-Quintanar A. The use of iontophoresis in the administration of nicotine and new non-nicotine drugs through the skin for smoking cessation. *Curr Drug Discov Technol*. 2009;6(3):171–185.
48. Melero A, Garrigues TM, Alos M, Kostka KH, Lehr CM, Schaeffer UF. Nortriptyline for smoking cessation: release and human skin diffusion from patches. *Int J Pharm*. 2009;378(1–2):101–107.
49. Merino V, Mico-Albinana T, Nacher A, Diaz-Sales O, Herrera M, Merino-Sanjuan M. Enhancement of nortriptyline penetration through human epidermis: influence of chemical enhancers and iontophoresis. *J Pharm Pharmacol*. 2008;60(4):415–420.